Sino Medical Sciences Technology Future Growth
Future criteria checks 5/6
Sino Medical Sciences Technology is forecast to grow earnings and revenue by 109.6% and 41.1% per annum respectively. EPS is expected to grow by 109.2% per annum. Return on equity is forecast to be 6.1% in 3 years.
Key information
109.6%
Earnings growth rate
109.2%
EPS growth rate
Medical Equipment earnings growth | 23.8% |
Revenue growth rate | 41.1% |
Future return on equity | 6.1% |
Analyst coverage | Low |
Last updated | 25 Jun 2024 |
Recent future growth updates
No updates
Recent updates
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | 1,080 | 159 | 58 | 126 | 1 |
12/31/2025 | 689 | 63 | -7 | 47 | 1 |
12/31/2024 | 475 | 11 | -35 | 10 | 1 |
6/30/2024 | 396 | -2 | 2 | 54 | N/A |
3/31/2024 | 361 | -21 | -1 | 61 | N/A |
12/31/2023 | 343 | -40 | -11 | 57 | N/A |
9/30/2023 | 272 | -95 | -88 | -4 | N/A |
6/30/2023 | 244 | -121 | -155 | -47 | N/A |
3/31/2023 | 207 | -149 | -184 | -88 | N/A |
12/31/2022 | 193 | -162 | -222 | -111 | N/A |
9/30/2022 | 239 | -129 | -183 | -66 | N/A |
6/30/2022 | 226 | -120 | -210 | -84 | N/A |
3/31/2022 | 226 | -119 | -226 | -70 | N/A |
12/31/2021 | 194 | -131 | -219 | -60 | N/A |
9/30/2021 | 173 | -138 | -217 | -59 | N/A |
6/30/2021 | 230 | -90 | -135 | 5 | N/A |
3/31/2021 | 283 | -27 | -90 | 39 | N/A |
12/31/2020 | 327 | 22 | -42 | 71 | N/A |
9/30/2020 | 401 | 73 | 1 | 152 | N/A |
6/30/2020 | 404 | 74 | -19 | 153 | N/A |
3/31/2020 | 407 | 75 | -24 | 139 | N/A |
12/31/2019 | 436 | 90 | -42 | 138 | N/A |
9/30/2019 | 419 | 91 | -35 | 98 | N/A |
12/31/2018 | 380 | 89 | -1 | 98 | N/A |
12/31/2017 | 322 | 66 | N/A | 70 | N/A |
12/31/2016 | 266 | 29 | N/A | 42 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: 688108 is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2.9%).
Earnings vs Market: 688108 is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: 688108 is expected to become profitable in the next 3 years.
Revenue vs Market: 688108's revenue (41.1% per year) is forecast to grow faster than the CN market (13.3% per year).
High Growth Revenue: 688108's revenue (41.1% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: 688108's Return on Equity is forecast to be low in 3 years time (6.1%).